Neurocrine Biosciences (NBIX) Return on Capital Employed (2011 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Return on Capital Employed of 18.67% for Q2 2026, up 340.0% year-over-year from 4.24% in Q2 2025, and down 6.85% on a QoQ basis from 20.04% in Q1 2026.
Neurocrine Biosciences (NBIX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Return on Capital Employed for 16 years, with the latest figure at 18.67% in Q2 2026.
- Return on Capital Employed for Q2 2026 came in at 18.67%, up 340.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 18.67% (up 340.0% YoY), and the FY2025 annual result was 18.04%, down 112.0% from the prior year.
- Return on Capital Employed retreated to 18.67% in Q2 2026, from 20.04% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 20.04% in Q1 2026 and troughed at 3.69% in Q2 2022.
- A 5-year average of 13.3% and a median of 15.41% in 2025 frame the typical range for Return on Capital Employed.
- The widest annual swing landed in 2022, when Return on Capital Employed tumbled 508 bps; it then surged 1091 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 14.49% in 2022, then decreased by 28 bps to 10.48% in 2023, then soared by 75 bps to 18.29% in 2024, then retreated by 9 bps to 16.71% in 2025, then rose by 12 bps to 18.67% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 18.67% in Q2 2026, 20.04% in Q1 2026, and 16.71% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 3.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.67% |
| Mar 31, 2026 | 20.04% |
| Dec 31, 2025 | 16.71% |
| Sep 30, 2025 | 16.00% |
| Jun 30, 2025 | 15.27% |
| Mar 31, 2025 | 15.56% |
| Dec 31, 2024 | 18.29% |
| Sep 30, 2024 | 19.36% |
| Jun 30, 2024 | 17.93% |
| Mar 31, 2024 | 17.53% |
| Dec 31, 2023 | 10.48% |
| Sep 30, 2023 | 10.00% |
| Jun 30, 2023 | 7.91% |
| Mar 31, 2023 | 6.62% |
| Dec 31, 2022 | 14.49% |
| Sep 30, 2022 | 6.88% |
| Jun 30, 2022 | 3.69% |
| Mar 31, 2022 | 3.99% |
| Dec 31, 2021 | 5.70% |
| Sep 30, 2021 | 11.96% |